Logo image of VCNX

VACCINEX INC (VCNX) Stock Fundamental Analysis

NASDAQ:VCNX - Nasdaq - US9186403013 - Common Stock - Currency: USD

1.41  -2.24 (-61.37%)

After market: 1.3211 -0.09 (-6.3%)

Fundamental Rating

0

Taking everything into account, VCNX scores 0 out of 10 in our fundamental rating. VCNX was compared to 555 industry peers in the Biotechnology industry. VCNX has a bad profitability rating. Also its financial health evaluation is rather negative. VCNX has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year VCNX has reported negative net income.
In the past year VCNX has reported a negative cash flow from operations.
VCNX had negative earnings in each of the past 5 years.
In the past 5 years VCNX always reported negative operating cash flow.
VCNX Yearly Net Income VS EBIT VS OCF VS FCFVCNX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 -10M -20M -30M

1.2 Ratios

With a Return On Assets value of -382.72%, VCNX is not doing good in the industry: 96.62% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -382.72%
ROE N/A
ROIC N/A
ROA(3y)-344.5%
ROA(5y)-394.42%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
VCNX Yearly ROA, ROE, ROICVCNX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 0 500 -500 1K -1K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for VCNX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
VCNX Yearly Profit, Operating, Gross MarginsVCNX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 0 -5K -10K -15K -20K

More info and screens

0

2. Health

2.1 Basic Checks

VCNX does not have a ROIC to compare to the WACC, probably because it is not profitable.
VCNX has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, VCNX has more shares outstanding
The debt/assets ratio for VCNX is higher compared to a year ago.
VCNX Yearly Shares OutstandingVCNX Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 200K 400K 600K 800K
VCNX Yearly Total Debt VS Total AssetsVCNX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 5M 10M 15M 20M

2.2 Solvency

Based on the Altman-Z score of -116.17, we must say that VCNX is in the distress zone and has some risk of bankruptcy.
VCNX has a worse Altman-Z score (-116.17) than 98.04% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -116.17
ROIC/WACCN/A
WACC10.93%
VCNX Yearly LT Debt VS Equity VS FCFVCNX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 0 -10M -20M -30M

2.3 Liquidity

A Current Ratio of 0.77 indicates that VCNX may have some problems paying its short term obligations.
The Current ratio of VCNX (0.77) is worse than 90.39% of its industry peers.
A Quick Ratio of 0.77 indicates that VCNX may have some problems paying its short term obligations.
Looking at the Quick ratio, with a value of 0.77, VCNX is doing worse than 90.39% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 0.77
Quick Ratio 0.77
VCNX Yearly Current Assets VS Current LiabilitesVCNX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 5M 10M 15M 20M

More info and screens

0

3. Growth

3.1 Past

VCNX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 85.54%, which is quite impressive.
Looking at the last year, VCNX shows a very negative growth in Revenue. The Revenue has decreased by -51.19% in the last year.
VCNX shows a decrease in Revenue. Measured over the last years, the Revenue has been decreasing by -4.67% yearly.
EPS 1Y (TTM)85.54%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%81.47%
Revenue 1Y (TTM)-51.19%
Revenue growth 3Y-3.02%
Revenue growth 5Y-4.67%
Sales Q2Q%160%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
VCNX Yearly Revenue VS EstimatesVCNX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 200K 400K 600K 800K
VCNX Yearly EPS VS EstimatesVCNX Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 -200 -400 -600 -800

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

VCNX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
VCNX Price Earnings VS Forward Price EarningsVCNX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
VCNX Per share dataVCNX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -2 -4 -6 -8 -10

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for VCNX!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

VACCINEX INC

NASDAQ:VCNX (12/17/2024, 9:35:36 PM)

After market: 1.3211 -0.09 (-6.3%)

1.41

-2.24 (-61.37%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-11 2024-11-11/bmo
Earnings (Next)N/A N/A
Inst Owners51.85%
Inst Owner Change0%
Ins Owners0.38%
Ins Owner Change0%
Market Cap3.78M
Analysts85.71
Price TargetN/A
Short Float %0.11%
Short Ratio0.02
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 9.74
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-12.16
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-5.92
FCFYN/A
OCF(TTM)-5.91
OCFYN/A
SpS0.14
BVpS-0.49
TBVpS-0.49
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -382.72%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-344.5%
ROA(5y)-394.42%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.08
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 21.15%
Cap/Sales 5.67%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.77
Quick Ratio 0.77
Altman-Z -116.17
F-Score4
WACC10.93%
ROIC/WACCN/A
Cap/Depr(3y)41.02%
Cap/Depr(5y)49.77%
Cap/Sales(3y)17.1%
Cap/Sales(5y)22.52%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)85.54%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%81.47%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-51.19%
Revenue growth 3Y-3.02%
Revenue growth 5Y-4.67%
Sales Q2Q%160%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y11.64%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y19.53%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y19.23%
OCF growth 3YN/A
OCF growth 5YN/A